Business

Biotech, pharma, and money in science

Artificial intelligence
Biotech

Acadia Pharma drug fails to improve psychosis in schizophrenia patients

By Adam Feuerstein

MilliporeSigma sign
Exclusive

Fight for coveted CRISPR patents gets knottier, as MilliporeSigma makes new claims

By Sharon Begley

Biotech

Frequency signs $80 million deal with Astellas Pharma

By Jonathan Saltzman — Boston Globe

Vertex
Biotech

Weeks after Kymera signed $70m deal with Vertex, the biotech’s CEO is out

By Jonathan Saltzman — Boston Globe

unplug
Politics

After Trump pulled the plug on rebates, his options to reduce drug prices narrow. And he may need Congress

By Andrew Joseph and Damian Garde

Biotech

Mass. Gov. Charlie Baker’s plan to curb drug prices strains his relationship with biotechs

By Priyanka Dayal McCluskey — Boston Globe

Pharmalot

Pharmalittle: Trump abandons rebate rule; biotechs fume at Mass. governor’s plan to lower drug prices

By Ed Silverman

Parker book
In the Lab

The Parker Institute looks to grow, leveraging outside donors and equity stakes

By Rebecca Robbins

Biotech

Takeda, already a giant in Mass. biopharma, plans a bigger footprint

By Jonathan Saltzman — Boston Globe

Yoshitsugu Shitaka
Biotech

Stem-cell biotech seeing strong growth

By Jonathan Saltzman — Boston Globe

Lars Fruergaard Jorgensen
Pharmalot

Novo Nordisk’s Jorgensen: If it was easy to correct pricing, we would be doing it already

By Ed Silverman

Vascepa pill handout
Business

Amarin raises sales guidance for heart drug Vascepa, hires more sales reps for larger marketing push

By Adam Feuerstein

Scorecard
Biotech

The biotech scorecard for the third quarter: 12 stock-moving events to watch

By Adam Feuerstein

Holmes
Health

Ex-Theranos CEO Elizabeth Holmes gets a trial date: summer 2020

By Rebecca Robbins

Biotech

How Brent Saunders’ Allergan experiment failed

By Matthew Herper

athersys cells
Biotech

A stem cell company is touting a stroke survivor’s recovery. Its media blitz offers investors a mirage

By Adam Feuerstein

Capitol Building
Politics

Consumer genetic testing companies team up to lobby on privacy policy

By Andrew Joseph

AbbVie California
Business

AbbVie to acquire Allergan for $63 billion in megamerger of pharma giants

By Adam Feuerstein and Matthew Herper

UnitedHealth
Business

PatientsLikeMe, forced by U.S. to ditch Chinese investor, sold to UnitedHealth Group

By Matthew Herper

Steven Pearson
Business

It’s Pioneer Institute vs. ICER: Drug-pricing watchdog comes under fire for a ‘one-size-fits-all’ approach

By Jonathan Saltzman — Boston Globe

SPRAVATO
Politics

VA declines broad coverage for new J&J depression drug touted by Trump

By Lev Facher and Ed Silverman

WHO logo
Pharma

WHO rescinds opioid guidelines following criticism by two U.S. lawmakers

By Priyanka Dayal McCluskey — Boston Globe

Regeneron
Biotech

Rivals’ disappointing results in asthma trial drag down shares of AnaptysBio

By Adam Feuerstein

Radar operators 1954
Business

Federally funded research drives nearly one-third of U.S. patents, report finds

By Brittany Flaherty

Steven Pearson
Business

Drug-pricing watchdog group is ‘mouse that roared’

By Jonathan Saltzman — Boston Globe

Health Tech

Webinar: Progress and pitfalls in the AI-aided search for novel drugs

By Casey Ross and Kate Sheridan

Amazon
Business

Amazon looking to work directly with health plans and employers to sell prescription drugs, court documents say

By Casey Ross

Biotech

Bluebird’s gene therapy for a rare blood disease will cost $1.8 million. Cue the pricing debate

By Adam Feuerstein

sickle cell disease blood sample
Biotech

Global Blood’s sickle cell disease drug heads to the FDA, but questions about patient benefit still linger

By Adam Feuerstein

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy